These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 25680621)

  • 21. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.
    Zhao M; Zhang F; Chen Y; Dai H; Qu J; Dong C; Kang X; Liu Y; Yang L; Li Y; Zhou P; Pan CT; Zhang L; Liu P; Zhou H; Jiao X; Xiong Y; Tian R; Lu Y; Yu X; Li X
    JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy.
    Rouvas A; Stavrakas P; Theodossiadis PG; Stamatiou P; Milia M; Giannakaki E; Datseris I
    Eur J Ophthalmol; 2012; 22(3):417-22. PubMed ID: 21928269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy.
    Kim YK; Ryoo NK; Woo SJ; Park KH
    Am J Ophthalmol; 2015 Jul; 160(1):72-84.e1. PubMed ID: 25887629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy.
    Senturk F; Karacorlu M; Ozdemir H; Karacorlu SA; Uysal O
    Am J Ophthalmol; 2011 Feb; 151(2):303-9.e1. PubMed ID: 21168824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Half-dose photodynamic therapy targeting the leakage point on the fluorescein angiography in acute central serous chorioretinopathy: a pilot study.
    Kim KS; Lee WK; Lee SB
    Am J Ophthalmol; 2014 Feb; 157(2):366-373.e1. PubMed ID: 24184226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Photodynamic therapy for steroid-associated central serous chorioretinopathy.
    Lee TG; Kim JE
    Br J Ophthalmol; 2011 Apr; 95(4):518-23. PubMed ID: 20679080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The one-year results of half-dose photodynamic therapy with verteporfin in chronic or recurrent central serous chorioretinopathy.
    Jirarattanasopa P; Ratanasukon M; Bhurayanontachai P
    J Med Assoc Thai; 2012 Apr; 95 Suppl 4():S56-60. PubMed ID: 22696853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Son BK; Kim K; Kim ES; Yu SY
    Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.
    Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M
    Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K; Shinoda K; Imamura Y; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
    Am J Ophthalmol; 2012 Sep; 154(3):579-85. PubMed ID: 22818904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Uetani R; Ito Y; Oiwa K; Ishikawa K; Terasaki H
    Eye (Lond); 2012 May; 26(5):640-9. PubMed ID: 22573069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Half-Dose Verteporfin Photodynamic Therapy (hdPDT) in the Treatment of Central Serous Chorioretinopathy].
    Höhn F; Kretz FT; Beger I; Koch F; Auffarth GU; Singh P; Deuchler S; Koss MJ
    Klin Monbl Augenheilkd; 2016 Jul; 233(7):860-3. PubMed ID: 26609673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of metamorphopsia in chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy.
    Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
    Retina; 2014 May; 34(5):964-70. PubMed ID: 24406387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy.
    Russo A; Turano R; Morescalchi F; Gambicorti E; Cancarini A; Duse S; Costagliola C; Semeraro F
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1141-1148. PubMed ID: 28283732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy.
    Koytak A; Erol K; Coskun E; Asik N; Öztürk H; Özertürk Y
    Retina; 2010; 30(10):1698-703. PubMed ID: 20539254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial.
    Wu ZH; Lai RY; Yip YW; Chan WM; Lam DS; Lai TY
    Retina; 2011; 31(7):1378-86. PubMed ID: 21836413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes.
    Karakus SH; Basarir B; Pinarci EY; Kirandi EU; Demirok A
    Eye (Lond); 2013 May; 27(5):612-20. PubMed ID: 23519277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.